Tags

Type your tag names separated by a space and hit enter

Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study.
Vaccine. 2016 Jan 27; 34(5):650-655.V

Abstract

BACKGROUND

Tick-borne Encephalitis (TBE) is endemic in south-eastern Sweden as well as in the Baltic regions, Central Europe and Russia. Ageing and immunosuppressed individuals are more prone to severe disease and neurological complications. We assessed the immunogenicity of TBE-vaccine in rheumatoid arthritis (RA) patients treated with tumor necrosis factor-inhibitors (TNFi) and/or methotrexate (MTX).

METHODS

TBE vaccine, FSME-Immune(®) or Encepur(®), was administered to non-immune RA patients as well as age and gender matched healthy controls. Individuals <60 years of age were given three doses at month 0, 1, 12. Individuals ≥ 60 years old were given an additional priming dose at month 3, i.e. a total of four doses. Tick-borne encephalitis neutralizing antibodies were assessed by a rapid fluorescent focus inhibition test.

RESULTS

The study population consisted of 66 patients and 56 age and gender matched healthy controls. Median age was 58.5 years. The patients were either treated with TNFi (n=16), TNFi+MTX (n=36) or MTX (n=14). After the last TBE-vaccine dose, given one year after the first, 39% of the patients compared to 79% of the healthy controls had seroprotective levels (p=<0.05).

CONCLUSIONS

Standard TBE-vaccine schedule does not confer enough immunogenicity in this group of immunosuppressed patients, who should be carefully informed about a higher risk for vaccination failure and risk of infection when exposed in high-endemic areas.

Authors+Show Affiliations

Karolinska Institutet, Dept. of Medicine/Solna, Unit for Infectious Diseases, SE 17176 Stockholm, Sweden. Electronic address: katarina.brodin-hertzell@capiostgoran.se.Department of Medical Sciences, Section of Infectious Diseases, Uppsala University, SE 751 85 Uppsala, Sweden.Karolinska Institutet, Dept. of Medicine/Solna, Unit for Infectious Diseases, SE 17176 Stockholm, Sweden; Centre for Clinical Research, Sörmland, Uppsala University, SE 631 88 Eskilstuna, Sweden. Electronic address: lars.rombo@gmail.com.Dept. of Rheumatology, Inst. of Medical Sciences, Uppsala University, SE 751 85 Uppsala, Sweden. Electronic address: ann.knight@akademiska.se.Public Health Agency of Sweden, Nobels väg 18, SE 17182 Solna, Sweden. Electronic address: sirkka@vene.se.Karolinska Institutet, Dept. of Medicine/Solna, Unit for Infectious Diseases, SE 17176 Stockholm, Sweden; Dept. of Communicable Diseases Control and Prevention, Box 17533, SE-11891 Stockholm, Sweden. Electronic address: helena.hervius-askling@ki.se.

Pub Type(s)

Journal Article
Multicenter Study

Language

eng

PubMed ID

26718689

Citation

Hertzell, Katarina Brodin, et al. "Tick-borne Encephalitis (TBE) Vaccine to Medically Immunosuppressed Patients With Rheumatoid Arthritis: a Prospective, Open-label, Multi-centre Study." Vaccine, vol. 34, no. 5, 2016, pp. 650-655.
Hertzell KB, Pauksens K, Rombo L, et al. Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Vaccine. 2016;34(5):650-655.
Hertzell, K. B., Pauksens, K., Rombo, L., Knight, A., Vene, S., & Askling, H. H. (2016). Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. Vaccine, 34(5), 650-655. https://doi.org/10.1016/j.vaccine.2015.12.029
Hertzell KB, et al. Tick-borne Encephalitis (TBE) Vaccine to Medically Immunosuppressed Patients With Rheumatoid Arthritis: a Prospective, Open-label, Multi-centre Study. Vaccine. 2016 Jan 27;34(5):650-655. PubMed PMID: 26718689.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Tick-borne encephalitis (TBE) vaccine to medically immunosuppressed patients with rheumatoid arthritis: A prospective, open-label, multi-centre study. AU - Hertzell,Katarina Brodin, AU - Pauksens,Karlis, AU - Rombo,Lars, AU - Knight,Ann, AU - Vene,Sirkka, AU - Askling,Helena H, Y1 - 2015/12/22/ PY - 2015/10/05/received PY - 2015/12/04/revised PY - 2015/12/07/accepted PY - 2016/1/1/entrez PY - 2016/1/1/pubmed PY - 2016/9/30/medline KW - Immunosuppression KW - Methotrexate KW - Rheumatoid arthritis KW - TNF-inhibitors KW - Tick-borne encephalitis KW - Vaccination SP - 650 EP - 655 JF - Vaccine JO - Vaccine VL - 34 IS - 5 N2 - BACKGROUND: Tick-borne Encephalitis (TBE) is endemic in south-eastern Sweden as well as in the Baltic regions, Central Europe and Russia. Ageing and immunosuppressed individuals are more prone to severe disease and neurological complications. We assessed the immunogenicity of TBE-vaccine in rheumatoid arthritis (RA) patients treated with tumor necrosis factor-inhibitors (TNFi) and/or methotrexate (MTX). METHODS: TBE vaccine, FSME-Immune(®) or Encepur(®), was administered to non-immune RA patients as well as age and gender matched healthy controls. Individuals <60 years of age were given three doses at month 0, 1, 12. Individuals ≥ 60 years old were given an additional priming dose at month 3, i.e. a total of four doses. Tick-borne encephalitis neutralizing antibodies were assessed by a rapid fluorescent focus inhibition test. RESULTS: The study population consisted of 66 patients and 56 age and gender matched healthy controls. Median age was 58.5 years. The patients were either treated with TNFi (n=16), TNFi+MTX (n=36) or MTX (n=14). After the last TBE-vaccine dose, given one year after the first, 39% of the patients compared to 79% of the healthy controls had seroprotective levels (p=<0.05). CONCLUSIONS: Standard TBE-vaccine schedule does not confer enough immunogenicity in this group of immunosuppressed patients, who should be carefully informed about a higher risk for vaccination failure and risk of infection when exposed in high-endemic areas. SN - 1873-2518 UR - https://www.unboundmedicine.com/medline/citation/26718689/Tick_borne_encephalitis__TBE__vaccine_to_medically_immunosuppressed_patients_with_rheumatoid_arthritis:_A_prospective_open_label_multi_centre_study_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0264-410X(15)01820-4 DB - PRIME DP - Unbound Medicine ER -